论文部分内容阅读
目的:分析阿奇霉素联合红霉素在小儿支原体肺炎中的临床疗效和安全性。方法:选取2014年1月-2016年1月100例医院收治小儿支原体感染性肺炎患儿作为观察对象,随机分为观察组与对照组,每组各50例。对照组采用单药阿奇霉素治疗,观察组在对照组的基础上加入红霉素治疗。比较两组患儿的临床疗效,记录两组患儿治疗期间发生的不良反应。结果:观察组患儿的治疗有效率显著高于对照组患儿(P<0.05);观察组不良反应发生率明显低于对照组(P<0.05)。结论:阿奇霉素联合红霉素在小儿支原体肺炎中具有较好的临床疗效,并且具有较高的安全性,值得在临床中推广使用。
Objective: To analyze the clinical efficacy and safety of azithromycin combined with erythromycin in children with mycoplasma pneumonia. Methods: From January 2014 to January 2016, 100 children with mycoplasma pneumonia were admitted to our hospital from January 2014 to January 2016, and randomly divided into observation group and control group, with 50 cases in each group. Control group with single-agent azithromycin treatment, the observation group in the control group based on the addition of erythromycin treatment. The clinical effects of the two groups were compared, and the adverse reactions in the two groups were recorded. Results: The treatment efficiency in observation group was significantly higher than that in control group (P <0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group (P <0.05). Conclusion: Azithromycin combined with erythromycin in children with mycoplasma pneumonia has a good clinical efficacy, and has high safety, it is worth to promote the use of the clinic.